冷大气血通过向脂肪质量和与肥胖相关的蛋白质来控制代谢综合征
Xiaofeng Dai1, Shuo Feng2, Tian Li3
1National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China.
Pharmacological research
|April 2, 2025
概括
肥胖和代谢障碍源于炎症. 用新型抑制剂或冷大气等离子体 (CAP) 向FTO蛋白为这些广泛的健康问题提供了潜在的治疗策略.
科学领域:
- 生物医学科学 生物医学科学
- 分子生物学分子生物学
- 医学研究 医学研究
背景情况:
- 肥胖和代谢障碍是全球重大健康挑战.
- 长时间的炎症,由肥胖驱动,有助于代谢综合征,如脂肪肝,糖尿病,心血管疾病和癌症.
- 脂肪质量和与肥胖相关的蛋白质 (FTO) 参与了代谢障碍的发病,导致了FTO抑制剂的发展.
研究的目的:
- 探索肥胖和主要代谢问题的共同病理原因,确定长时间的炎症是关键因素.
- 审查FTO在促进代谢障碍中的作用,并评估当前的FTO抑制剂.
- 提出冷大气等离子体 (CAP) 作为一种新的治疗方法来治疗肥胖和相关的代谢综合征,可能通过准FTO.
主要方法:
- 关于肥胖,代谢问题和炎症之间的联系的文献综述.
- 分析FTO在代谢障碍病原发生中的作用.
- 介绍冷大气等离子体 (CAP) 作为一种潜在的治疗方式.
主要成果:
- 长时间的炎症被确定为一种常见的病理原因,将肥胖和主要的代谢问题联系在一起.
- 现有的FTO抑制剂显示出潜力,但需要优化疗效和副作用概况.
- 冷大气等离子体 (CAP) 显示出抗炎性质和临床安全性,表明其潜在的应用.
结论:
- 准FTO具有解决肥胖症和相关代谢障碍的巨大潜力.
- 迫切需要新型FTO抑制剂,以提高有效性和安全性.
- 冷大气等离子体 (CAP) 为肥胖和代谢综合征提供了一个有前途的新疗法,需要进一步研究其FTO向能力.
相关概念视频
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...